Skip to main content Accessibility help

Imipenem Resistance Among Pseudomonas aeruginosa Isolates Risk Factors for Infection and Impact of Resistance on Clinical and Economic Outcomes

  • Ebbing Lautenbach (a1) (a2) (a3), Mark G. Weiner (a4), Irving Nachamkin (a5), Warren B. Bilker (a2) (a3), Angela Sheridan (a5) and Neil O. Fishman (a1)...



To identify risk factors for infection with imipenem-resistant Pseudomonas aeruginosa and determine the impact of imipenem resistance on clinical and economic outcomes among patients infected with P. aeruginosa.


An ecologic study, a case-control study, and a retrospective cohort study.


A 625-bed tertiary care medical center.


All patients who had an inpatient clinical culture positive for P. aeruginosa between January 1, 1999, and December 31, 2000.


From 1991 through 2000, the annual prevalence of imipenem resistance among P. aeruginosa isolates increased significantly (P<.001 by the χ2 test for trend). Among 879 patients infected with P. aeruginosa during 1999-2000, a total of 142 had imipenem-resistant P. aeruginosa infection (the case group), whereas 737 had imipenem-susceptible P. aeruginosa infection (the control group). The only independent risk factor for imipenem-resistant P. aeruginosa infection was prior fluoroquinolone use (adjusted odds ratio, 2.52 [95% confidence interval {CI}, 1.61-3.92]; P<.001). Compared with patients infected with imipenem-susceptible P. aeruginosa, patients infected with imipenem-resistant P. aeruginosa had longer subsequent hospitalization durations (15.5 days vs 9 days; P = .02) and greater hospital costs ($81,330 vs $48,381; P<.001). The mortality rate among patients infected with imipenem-resistant P. aeruginosa was 31.1%, compared with 16.7% for patients infected with imipenem-susceptible P. aeruginosa (relative risk, 1.86 [95% CI, 1.38-2.51]; P<.001). In multivariable analyses, there remained an independent association between infection with imipenem-resistant P. aeruginosa and mortality.


The prevalence of imipenem resistance among P. aeruginosa strains has increased markedly in recent years and has had a significant impact on both clinical and economic outcomes. Our results suggest that curtailing use of other antibiotics (particularly fluoroquinolones) may be important in attempts to curb further emergence of imipenem resistance.


Corresponding author

Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, 825 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104–6021, (


Hide All
1.Fluit, AC, Jones, RN, Schmitz, FJ, Acar, J, Gupta, R, Verhoef, J. Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998. Clin Infect Dis 2000; 30:454460.
2.Pfaller, MA, Jones, RN, Doern, GV, Kugler, K. Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob Agents Chemother 1998; 42:17621970.
3.Hilf, M, Yu, VL, Sharp, JA, Zuravleff, JJ, Korvick, JA, Muder, RR. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlation in a prospective study of 200 patients. Am J Med 1989; 87:540546.
4.Vidal, F, Mensa, J, Almela, M, et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Arch Intern Med 1996; 156:21212126.
5.King, A, Shannon, K, Phillips, I. Resistance to imipenem in Pseudomonas aeruginosa. J Antimicrob Chemother 1995; 36:10371041.
6.Piddock, LJV. Mechanisms of resistance to fluoroquinolones: state-of-the-art 1992-1994. Drugs 1995; 49(Suppl 2):2935.
7.Suvarna, SK, Al-Wali, WI, Locke, TJ. Morphological changes in Pseudomonas aeruginosa secondary to ciprofloxacin. Histopathology 1997; 31: 8283.
8.Pai, H, Kim, JW, Kim, J, Lee, J, Choe, K, Gotoh, N. Carbapenem resistance mechanisms in Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 2001; 45:480484.
9.Harris, AD, Karchmer, TB, Carmeli, Y, Samore, MH. Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clin Infect Dis 2001; 32:10551061.
10.Gross, R, Morgan, AS, Kinky, DE, Weiner, M, Gibson, GQ, Fishman, NO. Impact of a hospital-based antimicrobial management program on clinical and economic outcomes. Clin Infect Dis 2001; 33:289295.
11.Deyo, RA, Cherkin, DC, Ciol, MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45:613619.
12.National Committee for Clinical Laboratory Standards (NCCLS). Performance Standards for Antimicrobial Susceptibility Testing. NCCLS approved standard M100-S11. Wayne, PA: NCCLS; 2001.
13.Armitage, P. Test for linear trend in proportions and frequencies. Biometrics 1955; 11:375386.
14.Kleinbaum, DG, Kupper, LL, Morgenstern, H. Epidemiologic research: principles and quantitative methods. New York: Van Nostrand Reinhold; 1982.
15.Mantel, N, Haenszel, W. Statistical aspects of the analysis of data from retrospective studies of disease. J National Cancer Institute 1959; 22:719748.
16.Hosmer, DO, Lemeshow, SL. Applied logistic regression. New York: Wiley and Sons; 1989.
17.Sun, GW, Shook, TL, Kay, GL. Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis. J Clin Epidemiol 1996; 49:907916.
18.Mickey, RM, Greenland, S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol 1989; 129:125137.
19.Cao, B, Wang, H, Sun, H, Zhu, Y, Chen, M. Risk factors and clinical outcomes of nosocomial multidrug resistant Pseudomonas aeruginosa infections. J Hosp Infect 2004; 57:112118.
20.Harris, AD, Smith, D, Johnson, JA, Bradham, DD, Roghmann, MC. Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients. Clin Infect Dis 2002; 34:340345.
21.Troillet, N, Samore, MH, Carmeli, Y. Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns. Clin Infect Dis 1997; 25:10941098.
22.Fukuda, H, Hosaka, M, Hirai, K, Iyobe, S. New norfloxacin resistance gene in Pseudomonas aeruginosa PAO. Antimicrob Agents Chemother 1990; 34: 17571761.
23.Aubert, G, Pozzetto, B, Dorche, G. Emergence of quinolone-imipenem cross-resistance in Pseudomonas aeruginosa after fluoroquinolone therapy. J Antimicrob Chemother 1992; 29:307312.
24.Kohler, T, Michea-Hamzehpour, M, Epp, SF, Pechere, JC. Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems. Antimicrob Agents Chemother 1999; 43:424427.
25.Livermore, DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002; 34:634640.
26.Ochs, MM, McCusker, MP, Bains, M, Hancock, RE. Negative regulation of the Pseudomonas aeruginosa outer membrane porin OprD selective for imipenem and basic amino acids. Antimicrob Agents Chemother 1999; 43:10851090.
27.Krcmery, V, Trup, J, Kunova, A, et al. Imipenem-resistant P. aeruginosa bacteremia in cancer patients: risk factors, clinical features, and outcome. Int J Clin Pharmacol Res 1996; 16:4349.
28.Carmeli, Y, Troillet, N, Karchmer, AW, Samore, M. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med 1999; 159:11271132.

Related content

Powered by UNSILO

Imipenem Resistance Among Pseudomonas aeruginosa Isolates Risk Factors for Infection and Impact of Resistance on Clinical and Economic Outcomes

  • Ebbing Lautenbach (a1) (a2) (a3), Mark G. Weiner (a4), Irving Nachamkin (a5), Warren B. Bilker (a2) (a3), Angela Sheridan (a5) and Neil O. Fishman (a1)...


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.